Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite presented as a subcutaneous formulation for injection use. It is employed as an immunosuppressant and disease‑modifying antirheumatic drug to treat autoimmune conditions and certain malignancies in adult patients by inhibiting key enzymes in folate metabolism, reducing abnormal cell proliferation and inflammation.

GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Methotrexate is used across several autoimmune and oncologic disease pathways to modify disease activity.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriatic arthritis: alleviates joint swelling and skin lesions. - Severe plaque psoriasis: decreases plaque formation and scaling. - Acute lymphoblastic leukemia: interferes with malignant cell replication. - Non‑Hodgkin lymphoma: limits tumor growth by disrupting DNA synthesis.

Methofill may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting: transient gastrointestinal upset. - Stomatitis: inflammation or ulceration of the oral mucosa. - Fatigue: general tiredness or weakness. - Elevated liver enzymes: mild hepatic irritation. - Mild bone‑marrow suppression: slight reduction in blood cell counts.

Serious or Rare Side Effects: - Severe liver toxicity: potential for hepatitis or fibrosis. - Pulmonary fibrosis: progressive lung scarring. - Pancytopenia: profound suppression of all blood cell lines. - Renal toxicity: impaired kidney function. - Life‑threatening infection: due to immunosuppression. - Cutaneous necrosis: skin ulceration at injection sites.

Before initiating Methofill, several safety considerations are recommended.

- Liver monitoring: perform baseline and periodic liver function tests. - Hematologic surveillance: check complete blood counts regularly. - Renal assessment: evaluate kidney function prior to and during therapy. - Infection risk: avoid use in active infections and monitor for signs of infection. - Contraception: ensure effective birth control for women of childbearing potential. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - NSAIDs: increase risk of bone‑marrow suppression and renal toxicity. - Trimethoprim/sulfamethoxazole: potentiate myelosuppression. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect methotrexate absorption. - Alcohol: can exacerbate hepatic toxicity.